2-(4-benzhydrylpiperazin-1-yl)ethan-1-amine | 24252-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-benzhydrylpiperazin-1-yl)ethan-1-amine
• 英文别名: 2-(4-diphenylmethyl-1-piperazinyl)-ethylamine；2-(4-benzhydryl-piperazine)-ethylamine；1-(2-aminoethyl)-4-diphenylmethylpiperazine；2-(4-benzhydrylpiperazin-1-yl)ethylamine；4-(2-aminoethyl)-1-(diphenylmethyl)piperazine；2-(4-diphenylmethylpiperazin-1-yl)ethylamine；1-diphenylmethyl-4-(2-aminoethyl)piperazine；2-(4-benzhydryl-1-piperazinyl)ethaneamine；N-benzhydryl-n'-(2-aminoethyl)piperazine；2-(4-Benzhydrylpiperazino)ethaneamine；2-(4-benzhydrylpiperazin-1-yl)ethanamine
• CAS: 24252-67-3
• 化学式: C₁₉H₂₅N₃
• 分子量: 295.428
• InChiKey: NBKIHCZTVDRVCA-UHFFFAOYSA-N

物化性质

• 沸点：
  198-199 °C(Press: 0.07 Torr)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-benzhydrylpiperazin-1-yl)ethan-1-amine 以69%的产率得到3-t-Butoxycarbonyl-4(R)-[2-(4-diphenylmethyl-1-piperazinyl) ethylcarbamoyl]-2-(3-pyridyl)thiazolidine
  参考文献：
  名称：

  Thiazolidinecarboxylic acid amide derivatives and their therapeutic uses

  摘要：

  具有联合抗过敏和抗哮喘活性的噻唑烷羧酸酰胺，具有对血小板活化因子的拮抗活性，其一般结构式如下：

  公开号：

  US05470851A1
• 作为产物：
  描述：

  二苯甲基哌嗪 在 potassium carbonate 、 一水合肼 、 sodium iodide 作用下， 以 乙醇 、 丁酮 为溶剂， 反应 6.5h， 生成 2-(4-benzhydrylpiperazin-1-yl)ethan-1-amine
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. I. Synthesis and structure-activity relationships of N-((4-substituted 1-piperazinyl)alkyl)-3-(aryl and heteroaryl)acrylamides.

  摘要：

  一系列新的丙烯酰胺衍生物（7-10）被合成。对这些化合物的抗过敏活性进行了评估，并考察了它们的结构-活性关系。化合物10d，即N[4-(4-二苯甲基-1-哌嗪基)丁基]3-(3-吡啶基)丙烯酰胺，在口服给药的大鼠被动皮肤过敏反应（PCA）测试中显示出与酮替芬相当或更优越的抗过敏活性。与酮替芬不同，10d在体外对5-脂氧合酶的抑制活性比咖啡酸更强，而其体外抗组胺活性则弱于酮替芬。此外，它对大鼠肥大细胞释放组胺的抑制活性约为色甘酸二钠（DSCG）的三分之二。化合物10d是一种有前途的多种过敏性疾病治疗药物。

  DOI：

  10.1248/cpb.37.100

文献信息

• Acrylamide derivatives as antiallergic agents. I. Synthesis and structure-activity relationships of N-((4-substituted 1-piperazinyl)alkyl)-3-(aryl and heteroaryl)acrylamides.
  作者：Yoshinori NISHIKAWA、Tokuhiko SHINDO、Katsumi ISHI、Hideo NAKAMURA、Tatsuya KON、Hitoshi UNO

  DOI：10.1248/cpb.37.100

  日期：——

  A new series of acrylamide derivatives (7-10) were synthesized. Antiallergic activity of these compounds was evaluated and their structure-activity relationships were examined. Compounds 10d, N[4-(4-diphenylmethyl-1-piperazinyl)buthyl]3-(3-pyridyl)acrylamide, showed antiallergic activity equivalent or superior to that of ketotifen in the rat passive cutaneous anaphylaxis (PCA) test by oral administration. Compound 10d, unlike ketotifen, had more potent in vitro 5-lipoxygenase inhibitory activity than caffeic acid, whereas its in vitro antihistamine activity was weaker than that of ketotifen. In addition, its inhibitory activity against histamine release from rat mast cells was approximately two-thirds as potent as that of disodium cromoglycate (DSCG). Compound 10d is a promising agent for treating a variety of allergic diseases.

  一系列新的丙烯酰胺衍生物（7-10）被合成。对这些化合物的抗过敏活性进行了评估，并考察了它们的结构-活性关系。化合物10d，即N[4-(4-二苯甲基-1-哌嗪基)丁基]3-(3-吡啶基)丙烯酰胺，在口服给药的大鼠被动皮肤过敏反应（PCA）测试中显示出与酮替芬相当或更优越的抗过敏活性。与酮替芬不同，10d在体外对5-脂氧合酶的抑制活性比咖啡酸更强，而其体外抗组胺活性则弱于酮替芬。此外，它对大鼠肥大细胞释放组胺的抑制活性约为色甘酸二钠（DSCG）的三分之二。化合物10d是一种有前途的多种过敏性疾病治疗药物。
• Synthesis and histamine H1-receptor antagonist activity of 4-(diphenylmethyl)-1-piperazine derivatives with a terminal heteroaryl or cycloalkyl amide fragment
  作者：A Orjales、JC Gil-Sánchez、L Alonso-Cires、L Labeaga、R Mosquera、A Berisa、M Ucelay、A Innerárity、R Corcóstegui

  DOI：10.1016/0223-5234(96)83975-4

  日期：1996.1

  New 4-(diphenylmethyl)-1-piperazine derivatives with a terminal heteroaryl or cycloalkyl amide fragment were synthesized and evaluated for their antihistaminic, anticholinergic and antiallergic activities. Tested compounds were found to be moderate to potent in vitro (guinea-pig ileum) histamine H(1)-receptor antagonists. Derivatives with a four methylene chain (1e-1h) were as potent in vivo (capillary

  合成了具有末端杂芳基或环烷基酰胺片段的新的4-（二苯甲基）-1-哌嗪衍生物，并对其抗组胺，抗胆碱能和抗过敏活性进行了评估。发现测试的化合物是中等至有效的体外（豚鼠回肠）组胺H（1）-受体拮抗剂。具有四个亚甲基链（1e-1h）的衍生物在体内（大鼠的毛细血管通透性）与西替利嗪一样有效。发现杂芳基衍生物1e和1h是最活跃的试剂。这些化合物显示仅弱体外（豚鼠回肠）毒蕈碱M（3）-受体拮抗剂活性。在阻止化合物48/80诱导的组胺从大鼠腹膜肥大细胞释放方面，化合物1e和1g的效力比酮替芬高约100倍。导数1e 1f和1h不会改变大鼠口服100 mg / kg时的自发运动活动。已选择化合物1e进行进一步研究。
• Quantitative Structure–Activity Analyses of Novel Hydroxyphenylurea Derivatives as Antioxidants
  作者：Kazuya Nakao、Ryo Shimizu、Hitoshi Kubota、Mikiko Yasuhara、Yoshimasa Hashimura、Toshikazu Suzuki、Toshio Fujita、Hiroshi Ohmizu

  DOI：10.1016/s0968-0896(98)00039-x

  日期：1998.6

  importance in governing the inhibitory potency. An increase in the electron donating property of substituents toward the phenolic hydroxyl group enhanced the antioxidative activity by the stabilization of an electron-deficient radical-type transition state. The steric shielding by ortho-substituents stabilized the phenoxy radicals formed following the transition state. Derivatives having the carboxyl group

  合成了一系列取代的羟基苯基脲，其化学结构是基于天然抗氧化剂，维生素E（α-生育酚）和尿酸的结构设计的。它们显示出对脂质过氧化的高抑制活性。为了深入了解抑制反应的机理，我们定量分析了它们的构效关系。取代基对酚羟基的电子和空间效应显示出对控制抑制效力的重要性。取代基对酚羟基的给电子性的增加通过稳定电子缺陷的自由基型过渡态而增强了抗氧化活性。邻位取代基的空间屏蔽作用稳定了过渡态后形成的苯氧基。推测具有羧基的衍生物仅是弱活性的，这是因为酚羟基与羧酸根阴离子的分子间离子-偶极相互作用会延迟过渡态的形成。
• Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity
  作者：A. Dassonville-Klimpt、J. Schneider、C. Damiani、C. Tisnerat、A. Cohen、N. Azas、M. Marchivie、J. Guillon、C. Mullié、P. Agnamey、Anne Totet、J. Dormoi、N. Taudon、B. Pradines、P. Sonnet

  DOI：10.1016/j.ejmech.2021.113981

  日期：2022.1

  infections in the world. Herein, five new series of aminoalcohol quinolines including fifty-two compounds were designed, synthesized and evaluated in vitro against Pf3D7 and PfW2 strains. Among them, fourteen displayed IC50 values below or near of 50.0 nM whatever the strain with selectivity index often superior to 100.17b was found as a promising antimalarial candidate with IC50 values of 14.9 nM and

  疟疾是世界上第五大致命的寄生虫感染。在此，设计、合成了五个新系列的氨基醇喹啉，包括 52 种化合物，并在体外针对Pf 3D7 和Pf W2 菌株进行了评估。其中，14 株的 IC 50值低于或接近 50.0 nM，无论选择性指数通常高于 100 的菌株。发现17b是一种有希望的抗疟候选药物，对Pf 3D7 和Pf的 IC 50值分别为 14.9 nM 和 11.0 nMW2 和高于 770 的选择性指数，无论细胞系是什么。在对伯氏疟原虫ANKA 感染的小鼠模型进行体内研究之前，进行了进一步的实验以确认安全性并建立化合物17b的初步 ADMET 谱。该研究的总体数据允许建立新的结构-活性关系并开发具有改进药代动力学特性的新型药物。
• Hydantoin derivatives for treating complications of diabetes and
  申请人：Sanwa Kagaku Kenkyusho Co., Ltd.

  公开号：US05164391A1

  公开（公告）日：1992-11-17

  The invention relates to a hydantoin derivative, salt thereof, process for the preparation thereof, and medicine containing the derivative. The derivative is represented by the formula ##STR1## wherein M is --CONH--NHR.sup.1 group, --CONH--OR.sup.2 group, ##STR2## in which R.sup.1 is hydrogen atom, an alkyl group, an alkenyl group, a phenyl radical, a substituted phenyl group, a naphthyl radical, a substituted naphthyl group, a pyridyl radical, a furyl radical or a thienyl radical, R.sup.2 is a hydrogen atom, an alkyl group, a phenyl radical or a substituted phenyl group, R.sup.3 and R.sup.4 are the same or different independently, each being a phenyl radical, or an aralkyl group, or R.sup.3 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.4 and a possible nitrogen or oxygen atom, R.sup.5 forms a substituted or non-substituted saturated heterocyclic ring together with R.sup.6 and a possible nitrogen or oxygen atom, R.sup.7 is a nitroxy radical or a heteroaryl group, .sub.m and .sub.n are an integer of 2 to 5, Q is a hydrogen atom or ##STR3## in which R.sup.8 and R.sup.9 are the same or different independently, each being a substituted or non-substituted alkyl group, or R.sup.8 may form a substituted or non-substituted C.sub.5-6 saturated heterocyclic ring together with R.sup.9 and a possible nitrogen or oxygen atom, .sub.r is an integer of 2 to 5, T and X are the same or different independently, each being a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or an alkylmercapto group, and Z is an oxygen or sulfur atom. The derivatives and salts thereof are useful for the treatment of complications of diabetes and circulatory diseases.

  该发明涉及一种咪唑烷酮衍生物及其盐，其制备方法以及含有该衍生物的药物。该衍生物由以下结构表示：其中 M 是--CONH--NHR.sup.1基团，--CONH--OR.sup.2基团，R.sup.1 是氢原子，烷基，烯基，苯基，取代苯基，萘基，取代萘基，吡啶基，呋喃基或噻吩基，R.sup.2 是氢原子，烷基，苯基或取代苯基，R.sup.3 和 R.sup.4 独立相同或不同，各自是苯基或芳基烷基，或 R.sup.3 可与 R.sup.4 一起形成取代或非取代的C.sub.5-6饱和杂环环，其中可能包括一个氮原子或氧原子，R.sup.5 与 R.sup.6 一起形成取代或非取代的饱和杂环环，其中可能包括一个氮原子或氧原子，R.sup.7 是亚硝基基团或杂芳基团，m 和 n 是2到5的整数，Q 是氢原子或##STR3##，其中 R.sup.8 和 R.sup.9 独立相同或不同，各自是取代或非取代的烷基，或 R.sup.8 可与 R.sup.9 一起形成取代或非取代的C.sub.5-6饱和杂环环，其中可能包括一个氮原子或氧原子，r 是2到5的整数，T 和 X 独立相同或不同，各自是氢原子，卤原子，烷基，烷氧基或烷巯基，Z 是氧原子或硫原子。这些衍生物及其盐对于治疗糖尿病和循环疾病的并发症是有用的。